Atlantanews Online

Epilepsy Pipeline: Emerging Pipeline Therapies, Companies, Clinical Trials, Growth Prospects, and Treatment Landscape

 Breaking News
  • No posts were found

Epilepsy Pipeline: Emerging Pipeline Therapies, Companies, Clinical Trials, Growth Prospects, and Treatment Landscape

December 05
16:40 2022
Epilepsy Pipeline: Emerging Pipeline Therapies, Companies, Clinical Trials, Growth Prospects, and Treatment Landscape

DelveInsight’s, “Epilepsy Pipeline Insight, 2022” report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in the Epilepsy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.


Key takeaways from Epilepsy Pipeline Insight Report

  • DelveInsight’s Epilepsy Pipeline analysis depicts the space with 70+ active players working to develop 70+ pipeline therapies.
  • Major pharmaceutical companies are developing potential drug candidates to improve the Epilepsy treatment scenario, such as Otsuka Pharmaceutical Co. Ltd, Cerebral Therapeutics LLC, Marinus Pharmaceuticals, Xenon Pharmaceuticals, PTC Therapeutics, Eisai, Longboard Pharmaceuticals, Neurocrine Biosciences, and others.
  • Key Epilepsy pipeline therapies such as OPC-214870, CT-010, Ganaxolone, XEN496, Vatiquinone E-2730, LP352, NBI 827104, and others are under investigation in different phases of clinical trials.
  • The Epilepsy Companies and academics are working to assess challenges and seek opportunities that could influence Epilepsy R&D. The therapies under development are focused on novel approaches to treat/improve Epilepsy.


Recent Developmental Activities in the Epilepsy Pipeline Insight

  • In January 2021, Addex Therapeutics announced that its partner Janssen Pharmaceuticals had received FDA’s Investigational New Drug (IND) approval to begin a Phase IIa proof of concept study with the selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulator (PAM), JNJ-40411813 (ADX71149), in patients with Epilepsy.
  • In October 2020, PTC Therapeutics announced the initiation of a registration-directed Phase II/III clinical trial to evaluate vatiquinone (PTC743) in patients with mitochondrial Epilepsy, the highly morbid condition of refractory seizures in children with inherited mitochondrial disease.


Request for Epilepsy sample report to learn more about trends in specific geographies @ Epilepsy Pipeline Outlook Report


Epilepsy Overview

Epilepsy is a chronic disorder that causes unprovoked, recurrent seizures. A seizure is a sudden rush of electrical activity in the brain. There are two main types of seizures. Generalized seizures affect the whole brain. Focal, or partial seizures, affect just one part of the brain. A mild seizure may be difficult to recognize. It can last a few seconds during which you lack awareness. Stronger seizures can cause spasms and uncontrollable muscle twitches, and can last a few seconds to several minutes. During a stronger seizure, some people become confused or lose consciousness. Afterward you may have no memory of it happening. Epilepsy is a fairly common neurological disorder that affects people around the world. In the United States, it affects about 3 million people. Anyone can develop epilepsy, but it’s more common in young children and older adults. It occurs slightly more in males than in females. Symptoms depend on the area of the brain in which seizure activity occurs and on type of seizure. Symptoms may include are : Stiff muscles ,Become stiff and Fall backwards ,muscles relax and go floppy ,confused ,Breathing becomes difficult ,unconscious ,visual disturbances / hallucinations ,uncontrollable jerking and shaking, called a “”fit”, losing awareness and staring blankly into space ,strange sensations, such as a “”rising”” feeling in the tummy, unusual smells or tastes, and a tingling feeling in your arms or legs and collapsing. Treatment can help most people with epilepsy have fewer seizures, or stop having seizures completely.


Epilepsy Pipeline Insight Report

Epilepsy Pipeline Insight, 2022″ report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Epilepsy pipeline landscape is provided which includes the disease overview and Epilepsy treatment guidelines. The assessment part of the report embraces, in depth Epilepsy commercial assessment and clinical assessment of the pipeline products under development.


Epilepsy Emerging Drugs Profile

XEN1101: Xenon Pharmaceuticals

Xenon 1101, a differentiated KV7 potassium channel opener, for treatment of epilepsy. The Kv7 potassium channel mechanism has been clinically validated with ezogabine, an earlier generation Kv7 opener that was approved by the FDA as an adjunctive treatment for adults with focal seizures with or without secondary generalization. XEN1101’s unique composition is chemically designed to improve upon potency, selectivity and pharmacokinetics, or PK, of ezogabine, and is not expected to have ezogabine’s composition-specific tissue pigmentation effects. XEN1101 is a novel, small molecule, selective KCNQ2/3 (KV7.2/7.3) potassium channel positive allosteric modulator being developed for the treatment of partial onset (focal) epilepsy. Enhancing the open state of KCNQ2/3 in neurons favors a hyperpolarized resting state, which reduces rapid action potential spiking. This mechanism has been clinically proven to be effective for treatment of partial onset seizures in adults with epilepsy with the KCNQ2/3 opener, retigabine.

Lu AG06466: Abide therapeutics

Lu AG06466 (formerly ABX 1431) is an oral, small molecule, being developed by Abide Therapeutics (now Lundbeck A/S), for the treatment of neuropathic pain, Epilepsy. Currently, the drug is in Phase I stage of development for the treatment of Epilepsy.

TAK-935: Takeda Pharmaceuticals

Soticlestat is a potent, highly selective, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H), with the potential to reduce seizure susceptibility and improve seizure control. CH24H is predominantly expressed in the brain, where it converts cholesterol into 24S-hydroxycholesterol (24HC) to adjust the homeostatic balance of brain cholesterol. 24HC is a positive allosteric modulator of the NMDA receptor and modulates glutamatergic signaling associated with epilepsy. Glutamate is one of the main neurotransmitters in the brain and has been shown to play a role in the initiation and spread of seizure activity. Recent literature indicates that CH24H is involved in over-activation of the glutamatergic pathway through modulation of the NMDA channel and that increased expression of CH24H can disrupt the reuptake of glutamate by astrocytes, resulting in epileptogenesis and neurotoxicity. Inhibition of CH24H by soticlestat reduces the neuronal levels of 24HC and may improve excitatory/inhibitory balance of NMDA channel activity.


Request for Sample to know more @ Epilepsy Clinical Trials Analysis


Epilepsy Pipeline Therapeutics Assessment

The Epilepsy Pipeline report proffers an integral view of the Epilepsy emerging novel therapies segregated by Stage, Product Type, Route of Administration, Molecule Type, and Mechanism of Action.


Epilepsy Pipeline Profile

There are approx. 70+ key companies which are developing the therapies for Epilepsy. The companies which have their Epilepsy drug candidates in the most advanced stage, i.e. phase II include, Xenon Pharmaceuticals.


Scope of the Epilepsy Pipeline Report 

  • Coverage: Global 
  • Epilepsy Companies: Otsuka Pharmaceutical Co. Ltd, Cerebral Therapeutics LLC, Marinus Pharmaceuticals, Xenon Pharmaceuticals, PTC Therapeutics, Eisai, Longboard Pharmaceuticals, Neurocrine Biosciences, and others.
  • Key Epilepsy Pipeline Therapies: OPC-214870, CT-010, Ganaxolone, XEN496, Vatiquinone E-2730, LP352, NBI 827104, and others.


Dive deep into rich insights into Epilepsy novel and emerging drugs and their analysis @ Epilepsy Emerging Therapies



Table of Content

  1. Introduction
  2. Epilepsy Executive Summary
  3. Epilepsy: Overview
  4. Epilepsy Pipeline Therapeutics
  5. Epilepsy Therapeutic Assessment
  6. Epilepsy– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Pre-Registration)
  8. Drug name: Company name
  9. Drug profiles in the detailed report…..
  10. Last Stage Products (Phase III)
  11. Drug name: Company name
  12. Drug profiles in the detailed report…..
  13. Mid Stage Products (Phase II)
  14. XEN1101: Xenon Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Epilepsy Key Companies
  21. Epilepsy Key Products
  22. Epilepsy – Unmet Needs
  23. Epilepsy – Market Drivers and Barriers
  24. Epilepsy – Future Perspectives and Conclusion
  25. Epilepsy Analyst Views
  26. Epilepsy Key Companies
  27. Appendix


Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Epilepsy drugs?
  • How many Epilepsy drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Epilepsy?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Epilepsy therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Epilepsy and their status?
  • What are the key designations that have been granted to the emerging drugs?


Get Epilepsy Emerging Therapies Report @ Epilepsy Companies and Drugs

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India

Related Articles